Vanguard Group’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-8,373,637
| Closed | -$2.93M | – | 4148 |
|
|
2016
Q3 | $2.93M | Buy |
8,373,637
+1,475,117
| +21% | +$517K | ﹤0.01% | 3241 |
|
|
2016
Q2 | $3.21M | Buy |
6,898,520
+153,637
| +2% | +$71.6K | ﹤0.01% | 3186 |
|
|
2016
Q1 | $9.17M | Buy |
6,744,883
+976,837
| +17% | +$1.33M | ﹤0.01% | 2658 |
|
|
2015
Q4 | $8.48M | Buy |
5,768,046
+106,901
| +2% | +$157K | ﹤0.01% | 2734 |
|
|
2015
Q3 | $8.95M | Buy |
5,661,145
+389,325
| +7% | +$615K | ﹤0.01% | 2667 |
|
|
2015
Q2 | $8.96M | Buy |
5,271,820
+497,633
| +10% | +$846K | ﹤0.01% | 2737 |
|
|
2015
Q1 | $6.64M | Buy |
4,774,187
+769,295
| +19% | +$1.07M | ﹤0.01% | 2848 |
|
|
2014
Q4 | $6.05M | Buy |
4,004,892
+247,959
| +7% | +$374K | ﹤0.01% | 2794 |
|
|
2014
Q3 | $7.74M | Buy |
3,756,933
+39,756
| +1% | +$81.9K | ﹤0.01% | 2609 |
|
|
2014
Q2 | $11.4M | Buy |
3,717,177
+571,626
| +18% | +$1.75M | ﹤0.01% | 2451 |
|
|
2014
Q1 | $7.86M | Buy |
3,145,551
+442,086
| +16% | +$1.11M | ﹤0.01% | 2600 |
|
|
2013
Q4 | $13.4M | Buy |
2,703,465
+203,039
| +8% | +$1.01M | ﹤0.01% | 2328 |
|
|
2013
Q3 | $5.67M | Buy |
2,500,426
+407,796
| +19% | +$926K | ﹤0.01% | 2669 |
|
|
2013
Q2 | $4.65M | Buy |
+2,092,630
| New | +$4.65M | ﹤0.01% | 2708 |
|
Vanguard Group's RXII Position: Q4 2016 in Review
Vanguard Group sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 8,373,637 shares — an estimated $2.93M sold.
Vanguard Group first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $13.4M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Vanguard Group reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Vanguard Group sold 8,373,637 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $2.93M.
- Vanguard Group first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Vanguard Group's GALENA BIOPHARMA INC COM position peaked at $13.4M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.